There are currently 9 active clinical trials seeking participants for Plaque Psoriasis research studies. The states with the highest number of trials for Plaque Psoriasis participants are .
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Total Dermatology, Birmingham, Alabama +180 locations
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Register for Updates
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04772079
Recruiting
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose le... Read More
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
07/29/2025
Locations: Instituto de Neumonologia Y Dermatologia, Ciudad Autonoma de Buenos Aires, Buenos Aires +62 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219
Recruiting
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +57 locations
Conditions: Plaque Psoriasis
Register for Updates
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330
Recruiting
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Oruka Therapeutics Investigative Site, Los Angeles, California +4 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226
Recruiting
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2025
Locations: Cahaba Research Inc, Birmingham, Alabama +159 locations
Conditions: Plaque Psoriasis
Register for Updates
Modifying PEST for Psoriatic Arthritis Screening
NCT06382051
Recruiting
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Novartis Investigative Site, Hamilton, Ontario +1 locations
Conditions: Plaque Psoriasis, Psoriatic Arthritis
Register for Updates
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726
Recruiting
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/30/2025
Locations: Clinical Site, Rogers, Arkansas +18 locations
Conditions: Plaque Psoriasis
Register for Updates
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
Recruiting
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Total Dermatology, Birmingham, Alabama +272 locations
Conditions: Plaque Psoriasis
Register for Updates
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
NCT05994976
Recruiting
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Innovaderm Research Inc., Montréal, Quebec
Conditions: Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa, Plaque Psoriasis, Palmoplantar Pustulosis
Register for Updates